TB-500 questions
The questions sound simple until a study changes the molecule, the route or the injury. These answers stop where the record stops.
What is TB-500?
TB-500 is the synthetic, N-acetylated Ac-LKKTETQ fragment of thymosin beta-4: seven amino acids corresponding to residues 17–23 of the larger protein. The letters TB refer to its thymosin-beta lineage. Its research designation supplies no approved therapeutic indication.
Have human trials tested TB-500?
No completed controlled human trial has established efficacy for the heptapeptide. The healthy-volunteer intravenous study and ophthalmic research concern full-length thymosin beta-4. I regard the preparation and molecule as essential qualifications whenever those human studies are mentioned.
Does TB-500 help muscle, tendon or ligament injuries?
Controlled human trials have not established that benefit. The sports-medicine review describes encouraging animal findings alongside scarce human safety data. In dystrophin-deficient mice, the full protein increased regenerating fibers without a significant strength gain. I’d need a functional outcome in an appropriate human trial before treating a recovery claim as established.
When might an injury heal?
There is no validated human healing timetable for TB-500. The rat skin-wound findings concern full-length thymosin beta-4 and measured resurfacing of a particular wound. They cannot set a timetable for a human tendon, ligament or muscle injury.
Does TB-500 reduce inflammation?
A human anti-inflammatory benefit of the fragment remains unestablished. The pro-resolving-pathway experiments studied full-length thymosin beta-4 in animal and cell settings. The organ-scar page explains why resolution of inflammation is a more specific question than a general claim of reduced swelling.
What are the TB-500 side effects?
There is no controlled human side-effect profile for the fragment. The full-protein Phase 1 study reported infrequent mild or moderate events under its short intravenous protocol. Anecdotal accounts describe symptoms such as tiredness, nausea, headache and local irritation; those accounts establish no rates. The effects page gives them room without treating them as trial findings.
Does TB-500 cause cancer?
Human evidence does not establish that claim. Tumor-model findings involving thymosin beta-4 and pancreatic cancer-cell work raise a theoretical concern about cell movement and vessel growth. I take the concern seriously while leaving the fragment’s human risk unquantified.
Can TB-500 cause autoimmune reactions?
An autoimmune effect of the fragment has not been established. FDA cites immunogenicity concerns and inadequate safety information. Immunogenicity means the possibility of an immune response to a substance; it does not establish a specific autoimmune disease. The record cannot settle long-term immune safety.
How does TB-500 compare with BPC-157?
They are distinct synthetic peptides. The 2026 musculoskeletal review places both among unapproved therapies with limited rigorous human safety data. Neither a shared recovery claim nor discussion of using them together supplies controlled human evidence for the combination.
Can a pharmacy compound TB-500?
A TB-500 prescription rests on a case-by-case clinical assessment; the withdrawn FDA nomination itself grants no compounding permission. A pharmacy’s ingredient eligibility and the applicable 503A or 503B requirements remain separate from a prescriber’s decision. The legal status page follows the dated record and the dose page covers the unresolved human half-life.